. We found a significant negative correlation between 25[OH]D and 24-h systolic BP (r = − 0.277, P = 0.043). This correlation persisted in backward stepwise multivariate analyses (β = − 0.337; P = 0.022), after adjustment for age, gender, body mass index, glomerular filtration rate, and PRA. We did not observe statistically significant correlation between 25[OH]D and PRA. We compared the allelic frequencies and genotype distribution between patients and controls, and FokI and BsmI VDR polymorphisms were not associated either with hypertensive status or with PRA. Further wide studies are needed to clarify this relationship. 
INTRODUCTION
The hormone 1,25-dihydroxyvitamin D (1, 25 [OH] 2 D) is known for its important role in regulating body levels of calcium and phosphorus and in modulating bone mineralization. 1 In addition to classic functions, it is implicated in endothelial function, vascular smooth muscle cell proliferation and probably blood pressure (BP) regulation. 2 Experimental studies showed that 1, 25 [OH] 2 D is a negative endocrine regulator of renin-angiotensin-aldosterone system (RAAS) 3 that acts by inhibiting the renin mRNA expression. This repression is independent of calcium metabolism, volume-and salt-sensing mechanisms, and angiotensin II feedback regulation. 4, 5 Optimal 25[OH]D levels in healthy persons have not been precisely defined. Many authors suggest that sufficient concentrations begin at 30 ng ml − 1 , whereas values between 29 and 21 ng ml − 1 are considered as insufficient, and that levels below 20 ng ml − 1 are indicative of Vitamin D deficiency. [6] [7] [8] [9] [10] Biological activities of 1, 25 [OH] 2 D are mediated by high-affinity receptors, and polymorphisms in the gene-encoding vitamin D receptor (VDR) appear to predispose the onset of hypertension. [11] [12] [13] The most studied VDR polymorphisms are FokI and BsmI. FokI polymorphism consists of a T to C transition that alters the start codon and modifies the length of the VDR protein. The result is a more active transcription factor. BsmI is a A to G nucleotide substitution located in intron 8 that affects the transcript stability. It is in linkage disequilibrium with other polymorphisms and his association with some diseases is likely due to this phenomenon. 14 Both of these polymorphisms have been associated with the risk for essential hypertension with mixed results. [11] [12] [13] 15 However, the number of studies conducted in this regard is still low.
Moreover, several clinical studies showed an inverse association between low serum 25 [OH]D concentration and high BP, [16] [17] [18] [19] [20] [21] whereas other investigations were in contrast with those results. [22] [23] [24] The purpose of our study was to analyze the relationship between 25 [OH]D serum levels and clinic and 24-h ambulatory BP values in essential hypertensive (EH) patients, and to identify any possible association between hypertension and the VDR gene polymorphisms FokI and BsmI.
MATERIALS AND METHODS
In accordance with the Declaration of Helsinki and institutional guidelines, the protocol was approved by the local ethical committee, and patients were aware of the investigational nature of the study and agreed to participate after informed consent.
In 71 EH patients, aged 18-75 years, clinical BP, 24-h ambulatory BP monitoring, routine blood chemistry, 25[OH]D plasma level and plasma renin activity (PRA) were studied. Furthermore, FokI and BsmI VDR polymorphisms were analyzed and compared with those of 72 controls, blood donors, matched for age and sex, from the same geographical area.
Exclusion criteria were: secondary or malignant hypertension, diabetes or fasting glycaemia ⩾ 126 mg dl − 1 , heart failure, positive history or clinical signs of ischemic heart disease, cerebrovascular disease, chronic kidney disease and major noncardiovascular diseases. 1 All patients taking antihypertensive drugs underwent pharmacological washout for at least 2 weeks.
A careful clinical physical examination was carried out and anthropometric parameters (weight, height, body mass index (BMI) and waist circumference) were measured.
Clinic BP was recorded in a seated posture by a doctor. It was taken as the average of three consecutive measurements obtained using an automated sphygmomanometer, after the patient had rested for 5 min.
The 24-h ambulatory BP monitoring was performed using a non-invasive SpaceLabs 90207 recorder (Redmond, WA, USA). Only records with 480% valid data were accepted.
Subjects were instructed to ingest a diet containing 130-140 mmol per day of sodium and 40-50 mmol per day of potassium before the biochemical evaluation.
After an overnight fast of at least 10 h and after resting for 1 h in the supine position, patients underwent blood sampling for routine blood chemistry, 25 [OH]D, PRA and VDR genotype determination.
Determination of routine biochemical parameters was performed with standard techniques by using an autoanalyzer (Hitachi system 911, Boehringer Mannheim, Mannheim, Germany).
Glomerular filtration rate was estimated by both Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 25 The FokI and BsmI VDR gene polymorphisms were analyzed by PCR-RFLP. The DNA was extracted from peripheral blood with standard methods using QIAamp DNA Blood mini kit (Qiagen GmbH, Hilden, Germany). DNA amplification was carried out on a thermal cycler. Subsequently, VDR gene polymorphisms were typed by restriction enzyme digestion. The digested samples were analyzed by electrophoresis on 2% agarose gel.
Statistics
Statistical analysis was conducted using SYSTAT DATA software package, version 13 (Systat, San Jose, CA, USA).
Normal distribution of the continuous variables was assessed using the Kolmogorov-Smirnov test.
Non-Gaussian distribution was observed for all of the examined variables. For this reason, we analyzed these data using nonparametric tests.
The continuous variables are represented as median and interquartile range.
Differences among groups were evaluated using Kruskal-Wallis test and Mann-Whitney U-test for continuous variables.
We examined univariate associations between 25 [OH]D and both clinic and 24-h ambulatory BP, and between these parameters and other variables using Pearson correlation coefficients. Backward stepwise multiple linear regression analysis was used to assess the independent correlates of 24-h systolic BP (SBP), using 24- 
RESULTS
The characteristics of the hypertensive patients are given in Table 1 .
It is of note that median 25 [OH]D levels were lower than 30 ng ml − 1 , a value to date considered as normal cutoff, notwithstanding a normal median eGFR value and a good sun exposure favored by geographical area of origin. Table 2 We observed a significant difference in clinic DBP among the three FokI genotypes (P = 0.018). The Mann-Whitney U-test disclosed significantly higher DBP values in patients with ff FokI genotype compared with those with Ff FokI genotype (P = 0.002; Figure 2 We compared allelic frequencies and genotype distribution between 71 patients and 72 controls (Table 3 ). FokI and BsmI genotypes were in Hardy-Weinberg equilibrium.
We did not find any association between a specific genotype or allele and hypertension. Moreover, no association between polymorphisms and PRA was pointed out. 21 In contrast to these data, in other studies the relationship between 25 [OH]D concentrations and BP values was not observed. [22] [23] [24] However, most of them were characterized by a limited number of population samples. Furthermore, it is noteworthy that only a poor percentage of patients of the study populations had vitamin D deficiency. 22 Several mechanisms have been postulated to explain the relationship between Vitamin D and BP, including regulatory action on proinflammatory cytokines, direct effect on vascular wall and upregulation of RAAS, the latter reported in studies in knockout mice for VDR. 3 It has been hypothesized that Vitamin D is a negative regulator of renin expression in vivo in humans. 27 In the hypertensive patients group we found low PRA and 25 [ In 184 normotensive individuals, Forman et al. 27 found higher PRA levels among those with 25 [OH]D deficiency and insufficiency; however, the association was not statistically significant. This is in line with our results, and it could be owing to the fact that the mechanisms of cell or tissue renin-angiotensin-aldosterone regulation by Vitamin D do not mirror sharply the systemic phenomena.
DISCUSSION
In recent years, several VDR polymorphisms have been identified and it has shown the existence of the possible relationships between these genetic variants and the risk for developing arterial hypertension.
The study by Muray et al. 11 was one of the first to highlight an association of BsmI genotype and BP, observing SBP values higher in apparently healthy men with bb genotype, than in the other genotypes. Neverthless, in healthy female genotypes were not associated with BP.
Another VDR polymorphism called into question is FokI, analyzed by Swapna et al. 12 who compared 280 hypertensive patients and 200 healthy controls and observed an association between the FF genotype and the risk for developing EH. 12 The existence of a relationship between the development of hypertension and FokI and BsmI VDR polymorphisms was also shown in a prospective study conducted by Wang et al. 13 in 1211 men free from hypertension at baseline, followed up for 15.3 years. Subjects with BB or Bb genotype had a hazard ratio for hypertension of 1.25 compared with bb genotype; with regard to FokI, men with ff genotype had a hazard ratio of 1.32 compared with FF and Ff carriers. In the same cohort an inverse association between 25 [OH]D and risk of hypertension was also observed.
Further, an association between FokI and PRA in combination with 25 [OH]D levels was demonstrated in hypertensive and normotensive individuals from the HyperPath cohort. 29 Our results do not confirm neither the existence of an association between VDR polymorphisms and hypertension, nor between these polymorphisms and PRA.
Indeed, very recently, a comprehensive genetic association study in a very wide population of men and women did not replicate the previously reported association between vitamin D-related single nucleotide polymorphisms and BP. 15 To the best of our knowledge, this is one of the few studies that comprehensively analyzes the relationship between BP, PRA, 25 [OH]D and the polymorphisms of the VDR, FokI and BsmI, in EH patients.
According to recent hypotheses, low 25 [OH]D levels lead to an upregulation of the RAAS, thus favoring the increase in BP.
In our study, although we found low 25 However, our study has some limitations, such as the small size sample, the observational nature and the unavailability of the PRA and 25 [OH]D values in the polymorphism control group.
In conclusion, although some studies have confirmed the existence of an association between VDR polymorphisms and the risk of hypertension, the comprehensive results do not seem to be conclusive and further wide studies are needed to clarify this relationship.
What is known about this topic?
• Human clinical studies analyzing 25 
